Abstract:Tuberculosis (TB) is an ancient infectious disease. Before the availability of effective drug therapy, it had high morbidity and mortality. In the past 100 years, the discovery of revolutionary anti-TB drugs such as streptomycin, isoniazid, pyrazinamide, ethambutol and rifampicin, along with drug combination treatment, has greatly improved TB control globally. As anti-TB drugs were widely used, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of emerged due to acquired genetic mutations, and this now presents a major problem for effective treatment. Genes associated with drug resistance have been identified, including mutations in isoniazid resistance, mutations in rifampin resistance, mutations in pyrazinamide resistance, and mutations in quinolone resistance. The major mechanisms of drug resistance include loss of enzyme activity in prodrug activation, drug target alteration, overexpression of drug target, and overexpression of the efflux pump. During the disease process, may reside in different microenvironments where it is expose to acidic pH, low oxygen, reactive oxygen species and anti-TB drugs, which can facilitate the development of non-replicating persisters and promote bacterial survival. The mechanisms of persister formation may include toxin-antitoxin (TA) modules, DNA protection and repair, protein degradation such as trans-translation, efflux, and altered metabolism. In recent years, the use of new anti-TB drugs, repurposed drugs, and their drug combinations has greatly improved treatment outcomes in patients with both drug-susceptible TB and MDR/XDR-TB. The importance of developing more effective drugs targeting persisters of is emphasized. In addition, host-directed therapeutics using both conventional drugs and herbal medicines for more effective TB treatment should also be explored. In this article, we review historical aspects of the research on anti-TB drugs and discuss the current understanding and treatments of drug resistant and persistent tuberculosis to inform future therapeutic development.

Unlocking the enigma of phenotypic drug tolerance: Mechanisms and emerging therapeutic strategies

Antibiotic tolerance among clinical isolates: mechanisms, detection, prevalence, and significance

Phenotypic heterogeneity in bacteria: the rise of antibiotic persistence, clinical implications, and therapeutic opportunities

Actionable mechanisms of drug tolerance and resistance in Mycobacterium tuberculosis

Proton motive force and antibiotic tolerance in bacteria

Antibiotic resistance and tolerance: What can drug delivery do against this global threat?

Drug resistance and tolerance in fungi

The past, present and future of tuberculosis treatment.

Decoding Bacterial Persistence: Mechanisms and Strategies for Effective Eradication

Bacterial Persister Cells and Development of Antibiotic Resistance in Chronic Infections: An Update

Enhanced Efflux Activity Facilitates Drug Tolerance in Dormant Bacterial Cells

Bacteria primed by antimicrobial peptides develop tolerance and persist

Molecular mechanism and application of emerging technologies in study of bacterial persisters

High-level carbapenem tolerance requires antibiotic-induced outer membrane modifications

Decoding antimicrobial resistance: unraveling molecular mechanisms and targeted strategies

Pleiotropic cellular responses underlying antibiotic tolerance in

Mechanisms of Bacterial Tolerance and Persistence in the Gastrointestinal and Respiratory Environments.

Exploring Phytochemicals for Combating Antibiotic Resistance in Microbial Pathogens

Molecular mechanisms of bacterial persistence and phenotypic antibiotic resistance.

Relationship and Conversion Between Persisters and Antimicrobial Resistant Bacteria

Antibiotic resistance and persistence—Implications for human health and treatment perspectives